Less Ads, More Data, More Tools Register for FREE

Pin to quick picksB8F.L Regulatory News (B8F)

  • There is currently no data for B8F

Director/PDMR Shareholding

4 Sep 2014 13:50

RNS Number : 8654Q
Biofrontera AG
04 September 2014
 



 

Biofrontera AG

 ("Biofrontera" or the "Company")

 

Director Dealing

 

Biofrontera AG (AIM:B8F), the European biopharmaceutical company, announces that on 4 September 2014 Thomas Schaffer, the Chief Financial Officer of the Company, purchased 2,000 ordinary shares of no par value in the capital of the Company ("Ordinary Shares") at a price of EUR 2.320 per Ordinary Share. Subsequent to this transaction Mr Schaffer has a beneficial interest in 10,088 Ordinary Shares representing 0.045% of the issued ordinary share capital of the Company.

 

For further information, please contact:

 

Biofrontera AG

 

 

Prof. Hermann Lübbert, Chief Executive Officer

Thomas Schaffer , Chief Financial Officer

Tel: + 49 (0) 214 - 87632 - 22

 

 

 

finnCap (Nomad and Broker)

 

Geoff Nash / Christopher Raggett (Corporate Finance)

Tel: 020 7220 0500

Steven Norcross(Corporate Broking)

 

 

 

Investor Relations

 

Seton Services

 

Toni Vallen

Tel: 020 7603 6797

 

 

Financial PR

Gable Communications

 

John Bick

Tel: 020 7193 7463

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSLIMTTMBIMBLI
12
Date   Source Headline
16th Feb 20161:58 pmRNSPrivate Placement
11th Feb 20163:30 pmRNSPhase III studies update
28th Jan 201610:28 amRNSExcellent results in Ameluz BCC clinical study
26th Jan 20169:49 amRNSFDA completes Ameluz NDA mid-cycle review
20th Jan 20167:00 amRNSNotice of Cancellation from Trading on AIM
7th Jan 20167:00 amRNSCE Marking Granted for IndoorLux® Collaboration
31st Dec 201511:57 amRNSTotal Voting Rights
23rd Dec 20152:30 pmRNSFDA Grants Small Business Waiver of US$2.3m
10th Dec 20157:00 amRNSIssue of equity and total voting rights
7th Dec 20157:00 amRNSMarketing approval for Ameluz® in Switzerland
23rd Nov 20153:05 pmRNSResult of Open Offer and Private Placement
20th Nov 20157:00 amRNS3rd Quarter Report
19th Nov 20158:00 amRNSFinal patient visit in Phase III trial for BCC
12th Nov 20151:00 pmRNSNotice of Q3 Results
11th Nov 201512:00 pmRNSBusiness Operations on Track
5th Nov 201511:32 amRNSFurther re: Subscription Price of New Shares
28th Oct 20153:23 pmRNSFurther re: Open Offer and Private Placement
27th Oct 201511:31 amRNSOpen Offer and Private Placement
2nd Oct 20157:00 amRNSFDA shortens review period for Ameluz
22nd Sep 20157:00 amRNSExcellent long term results of Phase III trial
14th Sep 20157:00 amRNSFDA accepts filing of Ameluz® and BF-RhodoLED®
1st Sep 20157:03 amRNSResult of AGM
14th Aug 20157:00 amRNSHalf Year Results
7th Aug 20157:00 amRNSNotice of Results
22nd Jul 20157:00 amRNSAppointment of Chief Commercial Officer
20th Jul 20157:00 amRNSBelixos® Protect product launch
17th Jul 20157:00 amRNSNotice of AGM
13th Jul 20159:45 amRNSFDA New Drug Application submitted for Ameluz®
22nd Jun 20157:00 amRNSFinal stage completed ahead of FDA submission
19th Jun 20156:10 pmRNSIssue of equity and total voting rights
29th May 20157:00 amRNSStrong Performance for Q1 2015
28th May 20157:00 amRNSResult of Open Offer & Private Placement
26th May 20157:01 amRNSNotice of First Quarter Results 2015
6th May 20157:02 amRNSPublication of PIII Study for Actinic Keratosis
27th Apr 20152:58 pmRNSFurther re Open Offer and Private Placement
23rd Apr 20151:36 pmRNSOpen Offer and Private Placement
20th Apr 20157:00 amRNSUS subsidiary and CEO US Operations Appointed
17th Apr 20157:00 amRNSQ1 Preliminary Trading Update
10th Apr 20157:00 amRNSFinal Results
8th Apr 20157:00 amRNSOff Market Block Trade Completed
30th Mar 20157:00 amRNSNotice of Results
25th Mar 20157:00 amRNSSales and Marketing of Ameluz® in Spain
26th Jan 20157:00 amRNSAmeluz Belgium launch and Clinical Trials Update
22nd Jan 20158:00 amRNSChange of Adviser
5th Dec 20149:00 amRNSBelixos(R) Gel addition to derma product range
26th Nov 20147:00 amRNSAmeluz International Approval Procedure
13th Nov 20147:00 amRNS3rd Quarter Results - 9mnths to 30 Sept 2014
7th Nov 20148:20 amRNSAmeluz distribution for Spanish market
27th Oct 201410:00 amRNSNotice of Q3 Results
20th Oct 20147:00 amRNSChange of Adviser
12

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.